TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Menlo Therapeutics Inc. (NASDAQ: MNLO) Investor Investigation Over Possible Violations Of Securities Laws

  • Investors who purchased shares of Menlo Therapeutics Inc. (NASDAQ: MNLO), have certain options and should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
Menlo Therapeutics Inc.
Security
NASDAQ: MNLO

Summary

An investigation on behalf of investors of Menlo Therapeutics Inc. (NASDAQ: MNLO) shares over potential securities laws violations by Menlo Therapeutics Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Menlo Therapeutics Inc. (NASDAQ: MNLO) concerning whether a series of statements by Menlo Therapeutics Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Redwood City, CA based Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. Menlo Therapeutics Inc. went public in early 2018.

On March 28, 2018, Menlo Therapeutics Inc. reported its fourth quarter and full year 2017 financial results and provided its financial outlook for the full year 2018. Menlo Therapeutics Inc. reported that its annual Total Revenue rose from $0.674 million in 2016 to $4.582 million in 2017 and that its Net loss rose from $14.068 million to $29.076 million in 2017.

Furthermore, Menlo Therapeutics Inc. stated that for the full year 2018, it expects operating expenses in the range of approximately$77.0 to $87.0 million, including stock-based compensation of approximately $3.0 to $6.0 million.

Shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) reached $38.824 per share on March 28, 2018.

On May 9, 2018, Menlo Therapeutics Inc reported its first quarter 2018 financial results. Menlo Therapeutics Inc reported a net loss of $12.7 million for the first quarter of 2018, compared to a net loss of $5.5 million for the same period in 2017. Furthermore, Menlo Therapeutics Inc, adjusted its financiaul outlook for the full year 2018. Menlo Therapeutics Inc said that it is lowering its operating expense guidance for the full year 2018 to a range of approximately $68.0 to $78.0 million.

Shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) closed on May 23, 2018, at $9.12 per share.

Start Monitoring Your Investments